June 2, 2026 07:21 AM EDT
StartupsR&D
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Kyle LaHucik
Biotech Correspondent
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine, pociredir for sickle cell disease, after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen.
TL;DRAI
Fulcrum Therapeutics abandons its sole clinical-stage sickle cell program following FDA feedback, pursuing exit. The move highlights tightening regulatory barriers in precision medicine, pressuring biotech consolidation and reshaping M&A landscape.
139 words~1 min read
